
Jan Scicinski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2904440/publications.pdf Version: 2024-02-01



IAN SCICINSKI

#	Article	IF	CITATIONS
1	Cancer and Beyond: Discovery and Development of NO-Releasing Therapeutics. , 2019, , 123-158.		1
2	The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. Clinical Epigenetics, 2017, 9, 4.	1.8	33
3	RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opinion on Investigational Drugs, 2017, 26, 109-119.	1.9	45
4	No patient left behind: The promise of immune priming with epigenetic agents. Oncolmmunology, 2017, 6, e1315486.	2.1	11
5	RRx-001 Reset: Chemoresensitization via NO-Mediated M1 Macrophage Repolarization. , 2017, , 35-56.		1
6	Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors. Oncotarget, 2017, 8, 102511-102520.	0.8	10
7	Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets. Case Reports in Oncology, 2016, 9, 285-289.	0.3	12
8	Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents. Biomolecules, 2016, 6, 32.	1.8	9
9	Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation. Medical Oncology, 2016, 33, 85.	1.2	11
10	Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial. Translational Oncology, 2016, 9, 108-113.	1.7	28
11	Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC. Respiratory Medicine Case Reports, 2016, 18, 62-65.	0.2	10
12	A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?. Medical Oncology, 2016, 33, 63.	1.2	15
13	Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case Reports in Oncology, 2016, 9, 164-170.	0.3	15
14	A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient after Priming with RRx-001. Clinical Medicine Insights: Oncology, 2016, 10, CMO.S40429.	0.6	12
15	RRx-001, A novel dinitroazetidine radiosensitizer. Investigational New Drugs, 2016, 34, 371-377.	1.2	37
16	RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors. Clinical Epigenetics, 2016, 8, 53.	1.8	20
17	Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy. Oncotarget, 2016, 7, 9041-9045.	0.8	5
18	Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. Oncotarget, 2016, 7, 40781-40791.	0.8	10

Jan Scicinski

#	Article	IF	CITATIONS
19	Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor. Case Reports in Oncology, 2015, 8, 461-465.	0.3	13
20	Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance. Neoplasia, 2015, 17, 716-722.	2.3	21
21	From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria. Malaria Journal, 2015, 14, 218.	0.8	15
22	Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget, 2015, 6, 19976-19989.	0.8	110
23	The War on Cancer: A Military Perspective. Frontiers in Oncology, 2015, 4, 387.	1.3	15
24	NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. Redox Biology, 2015, 6, 1-8.	3.9	98
25	Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock. Asian Journal of Transfusion Science, 2015, 9, 55.	0.1	15
26	Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncology, The, 2015, 16, 1133-1142.	5.1	76
27	Discovery and Development of RRx-001, a Novel Nitric Oxide and ROS Mediated Epigenetic Modulator. , 2015, , 259-277.		2
28	Targeting Hyponitroxia in Cancer Therapy. , 2015, , 39-48.		2
29	Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001. Oncotarget, 2015, 6, 21547-21556.	0.8	34
30	Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity. Oncotarget, 2015, 6, 43172-43181.	0.8	43
31	Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 1121-1127.	0.9	39
32	Follow the ATP: Tumor Energy Production: A Perspective. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 1187-1198.	0.9	64
33	Rewriting the Epigenetic Code for Tumor Resensitization: A Review. Translational Oncology, 2014, 7, 626-631.	1.7	37
34	Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy. Biochemical and Biophysical Research Communications, 2014, 447, 537-542.	1.0	35
35	Development of methods for the bioanalysis of RRx-001 and metabolites. Bioanalysis, 2014, 6, 947-956.	0.6	17
36	The Implications of Hyponitroxia in Cancer. Translational Oncology, 2014, 7, 167-173.	1.7	25

JAN SCICINSKI

#	Article	IF	CITATIONS
37	Abstract 1420: RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase. Cancer Research, 2014, 74, 1420-1420.	0.4	5
38	Abstract 2068: RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI In preclinical tumor models. Cancer Research, 2014, 74, 2068-2068.	0.4	3
39	Abstract 906: Molecular imaging of RRx-001-induced oxidative stress in Nrf2-luciferase expressing SCC VII tumors in mice. , 2014, , .		2
40	A phase 1 trial and pharmacokinetic study of RRx-001, a novel ROS-mediated pan-epigenetic agent Journal of Clinical Oncology, 2014, 32, 2578-2578.	0.8	4
41	The Capacity of Red Blood Cells to Reduce Nitrite Determines Nitric Oxide Generation under Hypoxic Conditions. PLoS ONE, 2014, 9, e101626.	1.1	28
42	Real Time Dynamic Imaging and Current Targeted Therapies in the War on Cancer: A New Paradigm. Theranostics, 2013, 3, 437-447.	4.6	18
43	Abstract LB-86: Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent , 2013, , .		1
44	Preclinical Evaluation of the Metabolism and Disposition of RRx-001, a Novel Investigative Anticancer Agent. Drug Metabolism and Disposition, 2012, 40, 1810-1816.	1.7	44
45	Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials. Cancer Research, 2012, 72, 2600-2608.	0.4	90
46	Oral Coadministration of Î ² -Glucuronidase to Increase Exposure of Extensively Glucuronidated Drugs that Undergo Enterohepatic Recirculation. Journal of Pharmaceutical Sciences, 2012, 101, 2545-2556.	1.6	8
47	Abstract 4371: RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors. Cancer Research, 2012, 72, 4371-4371.	0.4	10
48	Six Degrees of Separation: The Oxygen Effect in the Development of Radiosensitizers. Translational Oncology, 2011, 4, 189-198.	1.7	76
49	Abstract 676: Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Research, 2011, 71, 676-676.	0.4	2
50	NO or No NO, Increased Reduction of Nitrite to Nitric Oxide by Modified Red Blood Cells. Blood, 2011, 118, 2125-2125.	0.6	11
51	Microwave-assisted saccharide coupling with n-pentenyl glycosyl donors. Tetrahedron Letters, 2003, 44, 9051-9054.	0.7	39
52	Analytical Techniques for Small Molecule Solid Phase Synthesis. Current Medicinal Chemistry, 2002, 9, 2103-2127.	1.2	18
53	Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1399-1404.	1.0	30
54	Dihydropyrancarboxamides Related to Zanamivir:Â A New Series of Inhibitors of Influenza Virus Sialidases. 1. Discovery, Synthesis, Biological Activity, and Structureâ^'Activity Relationships of 4-Guanidino- and 4-Amino-4H-pyran-6-carboxamides. Journal of Medicinal Chemistry, 1998, 41, 787-797.	2.9	324

#	Article	IF	CITATIONS
55	Novel inhibitors of influenza sialidases related to GG167 structure-activity, crystallographic and Molecular dynamics studies with 4H-pyran-2-carboxylic acid 6-carboxamides. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 2931-2936.	1.0	58